Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 2/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GALR3 | O60755 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13245959 | 1.00 | MAPT (0.62) | MAPTPOLBNAMPTMMP2F2 | |
| SCHEMBL30267353 | 0.83 | ALDH1A1 (0.47) | MAPTPOLBMMP2MEN1ALDH1A1 | |
| SCHEMBL2148897 | 0.82 | CA2 (0.53) | MAPTPOLBMMP2F2PRSS1 | |
| SCHEMBL15152644 | 0.82 | L3MBTL1 (0.47) | MAPTPOLBF2PRSS1PRSS2 | |
| SCHEMBL2989019 | 0.82 | PKM (0.46) | MAPTMMP2F2PRSS1PRSS2 | |
| SCHEMBL13245962 | 0.82 | PKM (0.46) | MAPTMMP2F2PRSS1PRSS2 | |
| SCHEMBL15152645 | 0.82 | L3MBTL1 (0.47) | MAPTPOLBF2PRSS1PRSS2 | |
| SCHEMBL31200207 | 0.80 | MAPT (0.54) | MAPTPOLBNAMPTMMP2F2 | |
| SCHEMBL14345167 | 0.80 | PKM (0.44) | MAPTMMP2ALDH1A1PKMCA1 | |
| SCHEMBL1869601 | 0.79 | PKM (0.70) | MAPTPOLBALDH1A1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173958-A1 | COMPOUNDS FOR THE INHIBITION OF DGAT1 ACTIVITY | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| EP-2032547-A1 | COMPOUNDS FOR THE INHIBITION OF DGAT1 ACTIVITY | AstraZeneca AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007141545-A1 | COMPOUNDS FOR THE INHIBITION OF DGAT1 ACTIVITY | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173958-A1 | COMPOUNDS FOR THE INHIBITION OF DGAT1 ACTIVITY | DGAT1, DGAT2, ACAT2 | MAPT 1950/4885POLB 1547/4885NAMPT 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.